Latest news
BlossomHill Therapeutics, Clinical-Stage Oncology Drug Developer, Files for Nasdaq Global Select Market IPO - TradingViewTradingView · Fri, 07 Aug 2026 20:09:00 GMTInsilico Nominates AI-Designed ISM9077, Potential First-in-Class Y Inhibitor, as Preclinical Candidate - Bioengineer.orgBioengineer.org · Thu, 06 Aug 2026 03:03:47 GMTAI-designed first-in-class small-molecule inhibitor shows preclinical promise against pancreatic cancer - Bioengineer.orgBioengineer.org · Wed, 05 Aug 2026 22:18:47 GMTFirst-in-class small molecule inhibitor designed with AI support shows promise against pancreatic cancer in preclinical studies - Mayo Clinic News NetworkMayo Clinic News Network · Wed, 05 Aug 2026 13:41:08 GMTAcrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study - The Manila TimesThe Manila Times · Wed, 05 Aug 2026 12:40:43 GMTInsilico Medicine secures China NMPA IND clearance for AI-designed NLRP3 inhibitor ISM8969/HT-001 in Parkinson's - DealroomDealroom · Wed, 05 Aug 2026 07:13:43 GMTSpider-Man Accidentally Created The Greatest Weapon Against The X-Men In Brand New Day - The DirectThe Direct · Sat, 01 Aug 2026 17:18:29 GMTInsilico's AI-designed TEAD inhibitor secures FDA fast track for mesothelioma - AllSciAllSci · Fri, 31 Jul 2026 12:34:50 GMT